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Abstract
Since January 2020, the Novel Coronavirus Disease 2019 
(COVID-19) pandemic has dramatically impacted the world. In March 
2020, the COVID-19 epidemic reached Belgium creating uncertainty 
towards all aspects of life. There has been an impressive capacity and 
solidarity of all healthcare professionals to acutely reconvert facilities 
to treat these patients. In the context of liver transplantation (LTx), 
concerns are raised about organ donation shortage and safety, the ethics 
of using limited healthcare resources for LTx, selection criteria for LTx 
during the epidemic and the risk of de novo COVID-19 infection on the 
waiting list and after LTx.  BeLIAC makes several recommendations 
to try to mitigate the deleterious effect that this epidemic has/will have 
on donation and LTx, taking into account the available resources, and 
trying to maximize patients and healthcare professionals’ safety. (Acta 
gastroenterol. belg., 2020, 83, 340-343).
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Background
Since January 2020, the Novel Coronavirus Disease 
2019 (COVID-19) epidemic has dramatically impacted 
the world. In March 2020, the COVID-19 epidemic 
reached Belgium creating uncertainty towards all aspects 
of healthcare and questioning at the same time the 
challenge to both avoid viral dissemination and maintain 
standard of care for patients with other diseases. On the 
28th of April 47859 cases were confirmed in Belgium 
leading to 7501 deaths (1). 
The COVID epidemic has a particularly deleterious 
impact on liver transplantation (LTx) candidates. 
Nowadays, LTx still represents the only curative treatment 
for end stage liver diseases (2,3) and for hepatocellular 
carcinoma (HCC)  and other rare cancers (4,5). The risk 
for these patients is multiple. First, there is a risk that the 
liver disease progresses during the waiting time on the 
list, impeding the possibility to be transplanted or even 
worse leading to their death (6-8). Second, this epidemic 
leads to a shortage of healthcare resources (substantial 
reallocation of intensive care units (ICU) and healthcare 
providers to COVID-patients) and, in addition, to an 
acute-on-chronic shortage of donors (9,10), altogether 
seriously reducing the possibility to get a transplant (6). 
Third, there is a risk of acquiring COVID-19 early or late 
after transplantation and even while on the waiting list. 
In this epidemic context the aim of the Belgian 
Liver Intestine Transplant Committee (BeLIAC) was to 
provide a series of recommendations on the following 
aspects of LTx likely to be impacted by COVID-19: 
Donation, access to resources, selection criteria, pre-
listing evaluation, COVID-19 screening of recipients, 
the place of living donor related liver transplantation, 
and information to patients. These recommendations are 
meant to provide additional guidance for the care of these 
patients. They will have to be adapted during the course 
of time, according to the evolution of the epidemic, its 
impact on resources, and the increase knowledge we 
will gain of the effect of COVID-19 in LTx candidates 
and recipients. We will not address the situations of the 
middle- and long-term post-transplantation follow-up 
(surveillance, invasive procedures) nor the surveillance 
of patients with HCC and advanced liver failure. 
This publication is in line with the editorial policy of 




The reason for the reduction in organ donation is 
multifactorial: 1) less ICU resources for donor detection 
and management;  2) logistics and/or uncertainty 
about donor COVID-19 status; 3) less trauma victims 
(an indirect welcome effect of this crisis, but a small 
percentage of the donors); 4) a trend for more family 
refusals; and 5) the assumption in certain hospitals that 
donation/transplantation programs have been put on hold. 
This unprecedented shortage of both healthcare 
resources and donors has caused an unprecedented 
reduction in LTx activity. The “pre-epidemic baseline” 
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for the individual patient to whom this liver is allocated, 
and by the waiting line effect, this will impact the entire 
waiting list.  A contrario, cancelling a LTx will de facto 
reflect in increased mortality (8). 
4. BeLIAC recommends that LTx, by virtue of its 
life-saving nature, should be given priority access to 
non-COVID resources during this epidemic.
Selection of LTx recipients during the COVID epidemic
Belgium is part of Eurotransplant. Our country has 
one single national waiting list and livers procured in 
Belgium are shared nationally (with the exception of the 
hyper-urgent patients).
About two thirds of Belgian livers are allocated 
to particular patients based on the Model for End 
Stage Liver Disease (MELD). MELD allocation was 
introduced in 2007 to reduce mortality on the waiting 
list by distributing scarce liver grafts to the patients who 
would benefit the most (16). MELD is objective and 
transparent and takes into account elements of justice 
(greatest need) and of utility (greatest benefit). In short, 
MELD allocates a given liver to a given Belgian patient 
who at that given moment is the most urgent and most 
likely to benefit from this particular liver. 
About one third of Belgian livers (mostly non-heart 
beating donors) are allocated to the procuring center. For 
these livers, the team in charge (hepatologist/transplant 
surgeon) at that center selects the medically/surgically 
most suitable listed patient who at that given moment 
is the most urgent and most likely to benefit from this 
transplant. 
5. BeLIAC recommends not to deviate from the 
standard MELD allocation since it already makes an 
objective and transparent sorting of the most urgent 
patients. 
6. One exception to that might be LTx in patients 
with high exceptional MELD for non-oncological 
reasons and preserved liver function (for example 
polycystic disease, rare metabolic diseases ...), taking 
into account patient symptomatology (pain, pruritis, 
psychological distress ...). 
7. BeLIAC advocates an individualized decision 
making including a risk-benefit balance between the 
mortality on the waiting list without transplantation and 
the potential risk of peri- or  postoperatively acquired 
(in-hospital or after discharge) COVID-19 infection 
and related death, and -at the time of writing- the lack 
of specific treatment against COVID-19 (14, 17).
8. In the course of the epidemic and depending upon 
the COVID-induced scarcity of resources, BeLIAC 
recommends to take more into account the balance 
between expected resource utilization and anticipated 
outcome in patient selection.
9. BeLIAC recommends that, in case of a liver offer, 
the team in charge (hepatologist/transplant surgeon) 
decides upon the suitability of that offer for a particular 
patient. If the offer is deemed suitable and before it is 
mortality and drop-out rate (for progression of 
hepatocellular carcinoma (HCC) and/or a worsening 
medical condition) is about 15 % and will probably be 
impacted. We have to keep in mind that patients awaiting 
LTx are different from patients waiting for a kidney or for 
other solid organs since there is no middle- and long-term 
liver replacement therapy available. 
Other countries, such as China, have proposed 
guidelines for organ procurement (13). Some of these 
recommendations are difficult to implement in the real-
world practice with the spread of the epidemic (14). 
In this context, the BeLIAC makes the following 
recommendations:
1. BeLIAC recommends each transplant and 
procurement center together with their cooperating 
donor hospitals to assess the possible measures to 
facilitate and optimize the donation process during the 
epidemic. 
2. BeLIAC suggests to the Belgian Organ 
Procurement Committee (BEOPC) to follow the 
donation situation in Belgium and support donation 
activities wherever needed and however doable.
3. Although the risk of donor-derived COVID-19 
is unknown yet, use of COVID-19 positive donors 
(diagnosis made on chest-CTs, nasopharyngeal swab) 
should be prohibited given the risks to patients and 
healthcare staff. In accordance with the Belgian 
transplantation society (BTS) and the national 
transplant council guidelines (15), BeLIAC recommends 
that all donors should be tested by COVID-19 PCR on 
nasopharyngeal swab, chest-CT, or COVID-19 PCR 
on bronchiolo-alveolar lavage if clinically indicated 
(chest-CT not interpretable, lung contusion/trauma, ...)
Priority access to non-COVID resources for LTx 
recipients 
Transplantations are the only surgical procedures that 
are based on altruism, an important moral value in those 
difficult times. Organ donation has also an “instrumental” 
value essential to consider since it saves several lives. 
In an ideal situation with no shortage of donors and 
where “one size (liver) fits all (recipients)”, LTx could be 
postponed for a few weeks in selected recipients with not 
yet decompensated liver failure or with relatively stable 
HCC.
However, even in the pre-epidemic reality, this ideal 
scenario does not exist, and as already mentioned, the 
shortage of donors causes a “baseline” mortality/drop-
out of about 15% on the waiting list. 
With the COVID-19 epidemic and the additional donor 
shortage that it causes, the situation is aggravated. By the 
end of April 2020, the reduction in LTx activity (minus 
16 % compared to the same period in 2019) has led to 
an increase of 20 % in the number of patients registred 
on the waiting list (communication from Luc Colenbie, 
Federal public service). Even more than before, a 
suitable liver offer represents a unique life-saving chance 
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There are only limited data linking the underlying 
liver disease and a more severe course of COVID-19 
infection, but patients with advanced liver diseases 
should be considered at higher risk due to cirrhosis-
associated liver dysfunction (8).
In addition, there is a serious concern that 
immunosuppression may favor spreading of the virus and 
aggravate the disease (7).
However, preliminary data from the European Liver 
Transplant Registry (ELTR) suggest that the incidence 
of COVID-19 might not be particularly high(er) in the 
LTx population. By May 8th 2020, ELTR reported 311 
cases of COVID-19 in LTx recipients and 57 in wait 
listed candidates, among 125 european LTx centers. It 
has also been suggested that immunosuppression might 
not necessarily aggravate the disease, and might even be 
protective by downregulating the cytokine response (21). 
This information needs to be taken with extreme caution 
since data are incomplete at this stage and many patients 
may have self-quarantined. 
In fact, severe cases of COVID-19 and mortality 
in wait listed patients and in de novo and already 
transplanted recipients has been reported. In-hospital 
acquisition of COVID-19 in LTx patients or candidates 
has also been reported. Finally, LTx recipients often 
present several co-morbidities likely to make them 
more susceptible to COVID-19 related morbidity and 
mortality (age, overweight, cardiovascular disease, 
diabetes, hypertension etc..). As already mentioned, all 
these potential risks have to be taken into account in 
the risk versus benefit assessment and the final decision 
whether to proceed with LTx or not. 
14. BeLIAC recommends to inform wait listed 
patients of these possible risks of COVID-19 infection 
after LTx, and to give them the possibility to temporarily 
opt out from surgery on a case-by-case basis (particularly 
in those with quality-of-life indications).
Registries
Clearly, additional information is necessary to increase 
our knowledge on the effects of COVID-19 on LTx 
candidates and recipients, in order to take appropriate 
protective and curative measures, and to better inform 
patients(19). For this aim, various registries COVID-19 
in LTx recipients have been developed. 
● The ongoing ELTR registry:
Vincent Karam, ELTR manager, Paris, France 
vincent.karam-ext@aphp.fr & Wojciech Polak, Surgery, 
Rotterdam, Netherlands w.polak@erasmusmc.nl
● A newly created Bern registry:
Jean-Francois Dufour, Hepatology, Bern, Switzerland 
jean-francois.dufour@dbmr.unibe.ch & Frederik 
Nevens, Hepatology, Leuven, Belgium frederik.nevens@
uzleuven.be
● A newly created national registry (Belgian trans-
plantation society) for all solid organ transplants:
Laurent Weekers, Nephrology, Liège, Belgium 
actually accepted, intensivists and anesthesiologists are 
consulted to determine whether resources (ICU/OR/
Healthcare staff for non-COVID patients) do allow the 
LTx to take place. 
Pre-listing evaluation for LTx 
Timely evaluation of patients with chronic liver 
diseases, HCC and other malignancies , and their 
registration on the waiting list -if deemed appropriate 
candidates- is essential to accelerate access to LTx and 
decrease mortality (18).
10. BeLIAC recommends not to postpone evaluation 
of LTx candidates, unless for quality-of-life reasons 
only and depending upon patient symptoms.
COVID-19 screening at time of LTx
LTx in a COVID-19 infected recipient has to be 
avoided, given the risks for these patients and for the 
healthcare staff (7,19).
11. In accordance with the Belgian transplantation 
society and the national transplant council guidelines 
(15), BeLIAC recommends to screen recipients, at 
the time of hospital admission by Covid-19 PCR on 
nasopharyngeal swab and by chest-CT and cancel 
transplantation in case one or both are compatible with 
Covid-19 infection.
Living Donor Related Liver Transplantation (LDRLT)
LDRLT is usually programmed electively, except for 
specific indications such as liver tumors when it must be 
coordinated with the chemotherapy schedule, or in case 
of immediate vital risk. Patients may be simultaneously 
registered on the deceased waiting list; in these cases, 
LDRLT can be programmed when the risk for additional 
waiting time and death exceeds the benefit of deceased 
LTx. In the context of the COVID epidemic, we need to 
take into account that LDRLT uses extra non-COVID 
resources for the living donor and that here is a risk 
for the living donor of in-hospital or postoperatively 
acquired COVID-19 infection (20).
12. Depending upon the stage of the epidemic and 
the resources available, BeLIAC suggests to postpone 
LDRLT in stable patients, but not to delay LDRLT if 
specialists in charge consider that this would lead to 
additional vital risk.
13. Prior to planning LDRLT, BeLIAC recommends 
consulting with all specialists involved given the extra 
amount of non-COVID resources required for the 
donor. 
Information to patients 
There is uncertainty as to the impact of COVID-19 
on LTx patients. The risk of infection is present on the 
waiting list as well as after LTx. 
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15. BeLIAC recommends Belgian LTx centers to 
participate to these registries. 
Conclusion
The COVID-19 epidemic is a novel situation for all 
transplant specialists. This sanitary crisis is constantly 
evolving. All projections for the near future tell us that 
the COVID-19 is about to stay for at least a few months. 
Postponing the transplantation after the COVID-19 crisis 
is not feasible in the specific situation of LTx where no 
liver replacement therapies are available for patients with 
end-stage liver disease and where oncological aspects 
are at the forefront for patients suffering from HCC. 
Transplantation programs should receive prioritized 
access to non-COVID resources, while taking into 
account the benefit/risk balance of non-transplanting or 
developing de novo COVID-19 infection after LTx and 
maximizing patients and healthcare professionals’ safety.
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